The Fred Hutch Bone Marrow Transplant Program at Seattle Cancer Care Alliance is one of 17 stem cell transplant programs nationwide that outperformed its expected one-year survival rate for patients undergoing allogeneic transplants, and one of only five that have done so for the last four consecutive years. Allogeneic transplants use stem cells from a donor, whether related or unrelated to the patient.
These results were published by the Center for International Blood and Marrow Transplant Research (CIBMTR), which analyzed the National Marrow Donor Program’s (NMDP) registry of U.S. transplant centers over a three-year period for its 2016 Transplant Center-Specific Survival Report.
“Transplantation protocols have continued to evolve through clinical research. On the one hand, we have improved disease targeting thereby reducing relapse rates. On the other hand, we have reduced the toxicity of the transplant procedure and made strides in improving supportive care. Taken together, this has improved outcomes including survival for patients,” said Dr. Marco Mielcarek, medical director of the Adult Blood and Marrow Transplant Program at SCCA, and an associate member of the Clinical Research Division at Fred Hutchinson Cancer Research Center.
“The combined expertise of our transplant teams and support services ensures high-quality care and better-than-expected outcomes even for patients with a large burden of comorbid conditions,” Dr. Mielcarek said.
To arrive at its findings, CIBMTR independently examined the survival rates of 23,004 transplants performed to treat blood cancers at 179 U.S. centers in the NMDP network. The reporting period for the 2016 report covered January 1, 2012 to December 31, 2014. During this three-year period, 747 allogeneic transplants were performed at SCCA. The report, published annually, is required by federal law. It is designed to provide potential stem cell transplant recipients, their families, and the public with comparative survival rates among transplant centers.
Says Fred Appelbaum, MD, former executive director of SCCA and executive vice president and deputy director of the Hutch, “I’m very happy to see that our transplant patients during this period again had a survival that was better than predicted, and thus we “outperformed” in the language of the CIBMTR. The study’s findings reflect the extraordinary and long-standing dedication by the staff of the Hutch and SCCA to improve the outcomes of our patients by continually refining transplantation to be a safer and more effective treatment.”